Intervention not reported
TUMT · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments.…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
TUMT (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
PAE (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
PAE (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
CRFWVT (Rezūm) (pairwise) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
TIND (pairwise) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
CRFWVT (Rezūm) (indirect estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
TUMT (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
TIND (indirect estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
studies 1469 participants · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
1 finding from 1 review
Intervention not reported
PUL (UroLift) (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
PAE (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Mortality by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 90 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in mortality by day 90 compared with placebo (low certainty).
1 finding from 1 review
Clinical progression: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7) · hospitalised individuals with COVID‐19 (moderate to severe disease)
It is very uncertain whether bamlanivimab changes clinical progression: need for NIV, IMV, ECMO, or renal replacement… compared with placebo (very low certainty).
1 finding from 1 review
Quality of life · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to hospital discharge · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in time to hospital discharge up to 26.10.2020, absolute effects for… compared with placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in adverse events: grades 3 and 4 by day 30 compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in serious adverse events by day 30 compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Casirivimab/imdevimab showed no clear difference in mortality by day 30 compared with usual care alone (moderate certainty).
1 finding from 1 review